Transgene (LTS:0OCQ) Tariff Resilience Score: 4/10 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0OCQ Transgene SA LTS:0OCQ
49 GF Score
Price €0.76
GF Value €0.52
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Transgene Tariff Resilience Score?

Transgene LTS:0OCQ 49 Tariff Resilience Score is 4 as of Jul. 14, 2026. GuruFocus rates LTS:0OCQ with a GF Score™ of 49/100 and a GF Value™ of €0.52 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,370 Biotechnology companies, Transgene ranks better than 52.48% on this metric.

Transgene has the Tariff Resilience Score of 4, which implies that the company might have Average Resilient.

Transgene has High exposure due to reliance on international biotech supply chains. Manufacturing is primarily in Europe, with global sales. Previous tariffs have impacted costs, and limited pricing power exists in competitive markets.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Transgene might have Average Resilient.

Transgene  (LTS:0OCQ) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Transgene Tariff Resilience Score Related Terms

LTS:0OCQ vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Transgene's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Transgene Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transgene's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Transgene's Tariff Resilience Score falls into.


LTS:0OCQ
49GF Score
Transgene SA LTS:0OCQ
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 4 mean?
Transgene (LTS:0OCQ) has a Tariff Resilience Score of 4 as of Jul. 14, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Transgene ranks #651 out of 1370 companies in the Biotechnology industry, placing it in the top 47.5%.
Is Transgene's Tariff Resilience Score too high?
Transgene's current Tariff Resilience Score is 4. The Biotechnology industry median Tariff Resilience Score is 4.00. Transgene's value of 4 is 0% at this industry median. Based on the distribution chart, Transgene ranks #651 out of 1370 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Transgene has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Transgene's Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Transgene ranks #651 out of 1370 companies for Tariff Resilience Score. This puts Transgene in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Transgene's value of 4 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Transgene's current Tariff Resilience Score of 4 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Transgene's current Tariff Resilience Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgene stock overvalued right now?
Based on GuruFocus' analysis, Transgene (LTS:0OCQ) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.52, compared to a current price of €0.76 — trading 45.8% above its estimated fair value. The current Tariff Resilience Score is 4 and 0% at the Biotechnology industry median of 4.00. Transgene's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Transgene (LTS:0OCQ), the current Tariff Resilience Score is 4 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Transgene (LTS:0OCQ) Overvalued in 2026?

Based on GuruFocus' analysis, Transgene stock appears to be overvalued. The current stock price of €0.76 is trading 45.8% above its estimated GF Value™ of €0.52. GuruFocus considers Transgene to be Significantly Overvalued.

Key valuation signals for LTS:0OCQ:

  • Tariff Resilience Score: 4
  • GF Value™: €0.52 vs. price of €0.76 (45.8% above fair value)
  • GF Score™: 49/100 with 7 warning signs
  • Industry Position: 0% at the Biotechnology median (#651 of 1370)

No single metric tells the full story. See the LTS:0OCQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Transgene Business Description

Address 400, Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, Strasbourg, FRA, 67400
Transgene SA is a biotechnology company that designs and develops virus based immunotherapy products focused on the development of individualized therapeutic vaccines against cancers. The flagship program, TG4050, is an individualized therapeutic vaccine based on the myvac platform. The company also has other viral vector-based programs, including BT-001, an oncolytic virus based on the Invir.IO viral backbone, which is in clinical development. In addition, it conducts discovery and preclinical work, aimed at developing novel immunotherapies.
49GF Score

Get the complete analysis for LTS:0OCQ

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.76
Price
€0.52
GF Value